Goodbye job applications, hello dream career
Seize control of your career and design the future you deserve with LW career

Cochlear raises capital of up to $880m

Herbert Smith Freehills has advised Cochlear Limited on its capital raising of up to $880 million.

user iconTony Zhang 30 March 2020 Big Law
Michael Ziegelaar and Andrew Rich
expand image

Firms: Herbert Smith Freehills (Cochlear Limited)

Deal: Herbert Smith Freehills has advised Cochlear Limited on its capital raising, comprising a fully underwritten $880 million institutional placement and a non-underwritten share purchase plan to raise up to $50 million.

Cochlear has announced that due to significant demand received from domestic and global investors, the size of the placement was increased to $880 million (from the expected $800 million announced to the market at launch, on 25 March 2020).

Advertisement
Advertisement

Value: 880 million.

Area: Venture capital. 

Key players: The Herbert Smith Freehills team was led by partners Michael Ziegelaar and Andrew Rich, who were supported by senior associates Cecilia Mehl and Andrew Earle, and solicitors Jessica Voong and James Paolucci. 

The firm’s Australian team worked closely with HSF’s US securities lawyers, including partner Siddhartha Sivaramakrishnan and senior associate Jin Kong.

Deal significance: The offer forms part of a comprehensive capital raising package undertaken by Cochlear, which also includes a credit-approved commitment for an additional $150 million bank facility from an existing lender.

Cochlear is taking pre-emptive and decisive action to ensure that it remains strongly capitalised during current market uncertainties, and to position the company for the future.

Cochlear relationship partner, mr Rich, said, “It is great to see Cochlear and Herbert Smith Freehills working seamlessly together to achieve such a great outcome in globally challenging circumstances”.

Cochlear is the global leader in implantable hearing solutions, with an estimated market share globally of 60 per cent and in excess of 600,000 implants sold over the last 40 years.

Mr Ziegelaar, co-head of Australian equity capital markets further said on the deal: “We are really pleased that we could contribute to such a landmark capital raising in pretty tough market conditions – a capital raising that will strongly capitalise Cochlear for the future. It shows that for the right business, the capital markets are still open.”

JP Morgan acted as lead manager to the placement.

You need to be a member to post comments. Become a member for free today!